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ABSTRACT
The objective of this study was to determine the influ-
ence of pleural and ascitic fluid on the pharmacokinetics of
the antitumor camptothecin derivative topotecan. Four pa-
tients with histological proof of malignant solid tumor re-
ceived topotecan (0.45 or 1.5 mg/m2) p.o. on several occa-
sions in both the presence and absence of third space
volumes. Serial plasma and pleural or ascitic fluid samples
were collected during each dosing and analyzed by high-
performance liquid chromatography for both the intact lac-
tone form of topotecan and its ring-opened carboxylate
form. The apparent topotecan clearance demonstrated sub-
stantial interpatient variability but remained unchanged
within the same patient in the presence [110 6 55.6 liters/
h/m2 (mean 6 SD of eight courses)] or absence of pleural
and ascitic fluid [118 6 31.1 liters/h/m2 (mean 6 SD of seven
courses)]. Similarly, terminal half-lives and area under the
concentration-time curve ratios of lactone:total drug in
plasma were similar between courses within each patient.
Topotecan penetration into pleural and ascitic fluid demon-
strated a mean lag time of 1.61 h (range, 1.37–1.86 h), and
ratios with plasma concentration increased with time after
dosing in all patients. The mean ratio of third space topote-
can total drug area under the concentration-time curve to
that in plasma was 0.55 (range, 0.26–0.87). These data
indicate that topotecan can be safely administered to pa-
tients with pleural effusions or ascites and that there is
substantial penetration of topotecan into these third spaces,
which may prove beneficial for local antitumor effects.
INTRODUCTION
The increased risk of toxicity after chemotherapy in pa-
tients with pleural effusions and massive ascites is widely
known and has been well documented for several compounds
including methotrexate (1, 2) and fludarabine (3). This phenom-
enon is most likely related to greater drug accumulation in the
peripheral compartment and a slower transport back to the
central compartment, ultimately resulting in prolonged drug
exposure. For this reason, it is advisable to evacuate large
pleural and ascitic effusions before administration of these
agents. On the other hand, penetration of the delivered chemo-
therapeutic agent should be sufficient to produce adequate drug
distribution into the pleural or ascitic fluid to induce relevant
local antitumor effects (4).
Diffusion of p.o. or systemically administered drugs into
the peritoneum may be diminished by fibrous tissue due to prior
surgery or prior regional i.p. chemotherapy, as reported for
mitomycin C (4). In addition, several other factors including
molecular weight, hydrophobicity, blood and lymph flow, and
the capacity of the capillary wall and intervening interstitium
have been shown to affect the peritoneal-blood barrier (5). The
same factors may also be applicable for pleural effusions and the
pleural fluid-blood barrier, although few paired plasma/pleural
fluid pharmacokinetic data are available for antineoplastic
agents (5–7).
In the absence of any pharmacokinetic data on third space
sequestration for topotecan, a topoisomerase I inhibitor with
substantial antitumor activity against various malignancies (re-
viewed in Ref. 8), we have prospectively evaluated the extent of
penetration of this drug in pleural and ascitic fluid in cancer
patients and assessed the influence of these third spaces on
topotecan plasma pharmacokinetics.
MATERIALS AND METHODS
Patients and Treatment. Four patients with a histolog-
ically confirmed diagnosis of a malignant solid tumor that was
metastatic and progressive after prior therapy were studied (Ta-
ble 1). All patients had adequate hematopoietic (absolute neu-
trophil count $ 1.5 3 109/liter and platelet count $ 100 3
109/liter), hepatic (total serum bilirubin , 1.25 3 upper normal
limits), and renal (creatinine clearance $ 60 ml/min) function
(9). The study drug topotecan was supplied as capsules contain-
ing either 0.25 or 1.0 mg of the active compound (SmithKline
Beecham Pharmaceuticals Inc., Harlow, United Kingdom) and
administered p.o. once daily, after an overnight fast, either for 5
consecutive days and repeated every 3 weeks (three patients) or
for 2 consecutive days and repeated every week (one patient). In
all four patients, comedication was uniform and consisted of
cisplatin (50 or 70 mg/m2 administered as a 3-h i.v. infusion
immediately before topotecan on day 1 of every course) and
ondansetron (8 mg, i.v.) combined with dexamethasone (10 mg,
i.v.) given 30 min before cisplatin. During therapy, the patients
did not use any other medication that might have interfered with
topotecan absorption and disposition. The clinical protocol was
approved by the institutional review board, and patients signed
informed consent forms before entering the study.
Sample Collection. Material for pharmacokinetic analy-
sis was collected during the first treatment course on days 1, 2,
and 5 from patients on the 5-day schedule and during courses 1,
2, and 3 on days 1 and 2 from the patient on the 2-day schedule.
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Blood samples were collected in 4.5-ml glass tubes containing
lithium heparin as an anticoagulant (Becton Dickinson, Meylan,
France) and were obtained before dosing and 0.5, 1, 1.5, 2, 3, 4,
6, 8, and 12 h after topotecan administration. The blood samples
were placed immediately in an ice bath and centrifuged within
10 min at 3000 3 g for 5 min at 4°C to separate the plasma.
Subsequently, a volume of 250 ml of the plasma sample was
added to 750 ml of ice-cold (220°C) methanol in 2.0-ml
polypropylene vials (Eppendorf, Hamburg, Germany). After
vortex mixing for 10 s, the samples were stored at 280°C until
the day of analysis. Pleural and ascitic samples were obtained at
the same time points as blood samples using a Medicut 16GA
cannula (45 3 1.7 mm, internal diameter; Sherwood Medical,
Tullamore, Ireland) and collected in 4.5-ml polypropylene tubes
after discarding the first 10 ml of fluid. These samples were
processed as described above for plasma. To assess the extent of
drainage of all fluid, ultrasonography or chest X-ray was per-
formed after drainage.
Topotecan Assay. The samples, plasma as well as pleu-
ral liquid and ascites, were analyzed using reverse-phase high-
performance liquid chromatography with fluorescence detection
as described previously (10), with minor modifications. In brief,
samples were centrifuged for 5 min at 23,000 3 g at 4°C,
followed by a 5-fold dilution in PBS before the injection of
200-ml aliquots into the high-performance liquid chromatogra-
phy system. Chromatographic separations of topotecan carbox-
ylate and lactone forms and endogenous compounds were
achieved on a Hypersil BDS column (100 3 3 mm, internal
diameter; 3-mm particle size; Shandon, Cheshire, United King-
dom) that was maintained at 35°C. The mobile phase, composed
of 10 mM potassium dihydrogenphosphate-methanol-triethyl-
amine (1750:500:4, v/v/v) with the pH adjusted to 6.0 (or-
thophosphoric acid), was delivered at a flow rate of 0.70 ml/min.
The excitation and emission wavelengths of the Jasco FP920
fluorescence detector (Tokyo, Japan) were set at 381 and 525
nm, respectively, with an emission bandwidth of 40 nm. Chro-
matographic data analysis was performed based on peak height
measurements relative to injected standards using the Chrom-
Card system of Fisons (Milan, Italy).
Pharmacokinetic Analysis. Individual plasma concen-
trations of topotecan lactone and carboxylate forms were fit to a
linear two-exponential equation using the Siphar version 4 soft-
ware package (SIMED, Creteil, France), based on a variety of
considerations including Akaike’s and Schwarz’ information
criterion. The concentration-time profiles were obtained after
zero-order input, with a weighted least-squares algorithm apply-
ing a weighting factor of 1/y. The AUC2 values were determined
for both the lactone (AUCL) and carboxylate forms (AUCC) on
the basis of the best fitted curves. The apparent plasma CL/f was
calculated by dividing the dose administered by the observed
AUC. The apparent terminal disposition half-life (T1/2) was
calculated as ln2/kel, where kel is the observed elimination rate
constant of the terminal phase. The peak plasma concentrations
(Cmax) were determined graphically from the observed experi-
mental values. The L:T ratio was defined as AUCL/(AUCL 1
AUCC). The fraction of drug penetrating into pleural or ascitic
fluid was derived from the ratio of the topotecan total drug
AUCs in the third space and plasma.
RESULTS
Plasma Pharmacokinetics. Peak plasma concentrations
and AUCs of topotecan lactone after administration of a p.o.
dose of 1.50 mg/m2 to patients 1 and 2 were similar before and
after pleural fluid was drained (fluid volumes, 3.1 liters and 1.1
liter, respectively; Table 2). Complete drainage of all fluid was
confirmed by ultrasonography or chest X-ray after drainage.
Data from patient 3, who had recurrent ascites during all topo-
tecan administrations with volumes of 8.4 and 9.4 liters drained
on days 2 and 6, respectively, indicated no difference in phar-
macokinetic parameters between treatment days. Similarly, as-
cites (estimated to be 4.0 liters, 1.0 liter, and 1.0 liter on three
occasions by ultrasonography and percutaneous drainage) had
no measurable effect on topotecan plasma pharmacokinetics in
patient 4 (Table 2). Overall, the CL/f demonstrated substantial
interpatient variability but remained unchanged within the same
patient in the presence [110 6 55.6 liters/h/m2 (mean 6 SD;
eight courses)] or absence of pleural or ascitic fluid [118 6 31.1
liters/h/m2 (mean 6 SD; seven courses)]. Topotecan L:T ratios
in plasma were very similar between courses within each patient
and averaged 40.0 6 3.89% (drained) and 40.0 6 6.11% (not
drained), respectively.
Pleural and Ascitic Fluid Penetration. Given the low
plasma protein binding of topotecan (;35%; Ref. 11) and the
relatively high total protein content in pleural fluid and ascites
of the patients (range, 38–45 mg/ml), no correction for protein
binding was performed. Topotecan concentrations in pleural
fluid and ascites peaked at $6 h after oral dosing, demonstrating
a mean lag time of 1.61 h (range, 1.37–1.86 h; overall mean 6
SD in plasma, 0.63 6 0.28 h), and rose slowly to equal that in
plasma by ;8 h (Fig. 1, A–C). Topotecan disappearance from
pleural fluid [apparent T1/2, 12.0 h (n 5 1)] and ascites [apparent
T1/2, 8.0 h (n 5 1)] appeared to be slower than that from plasma.
As a result, third space penetration, expressed as the ratio of
concomitant pleural fluid or ascites:plasma concentration of
total topotecan, depended greatly on the sampling time point and
2 The abbreviations used are: AUC, area under the concentration-time
curve; CL/f, topotecan clearance; L:T, the ratio of the systemic exposure
of topotecan lactone to total drug.
Table 1 Patient characteristics
Characteristic Patient 1 Patient 2 Patient 3 Patient 4
Age (yr) 41 65 40 35
Gender M M M F
Carcinoma ACUPa Rectum ACUP Ovarian
Third space Pleural Pleural Ascites Ascites
Treatment schedule d1-5 q3w d1-5 q3w d1-5 q3w d1-2 q1w
Drug dose (mg/m2/day) 1.50 1.50 1.50 0.45
Drug dose (mg/day) 3.00 2.75 3.25 0.75 (d1)
1.00 (d2)b
a ACUP, adenocarcinoma of unknown primary origin; d1-5 q3w,
once daily for 5 consecutive days, repeated every 3 weeks; d1-2 q1w,
once daily for 2 consecutive days, repeated every week.
b As a result of body surface area-based dosing, and given the
availability of 0.25-mg and 1.0-mg topotecan capsules only, the calcu-
lated weekly dose was split into unequal daily doses.
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increased significantly with time in all patients (Fig. 1, D–F).
Overall, the mean ratio of third space topotecan total drug AUC
to that in plasma was 0.55 (range, 0.26–0.87). The hydrolysis of
topotecan to the ring-opened form was rapid, and L:T AUC
ratios were 18.1% and 23.5% in pleural fluid and 29.2% in
ascites. Measurement of topotecan in ascites from patient 3
indicated that less than 1% of the administered dose was present
in ascites at 6–8 h after dosing, indicating the lack of a sink
effect.
Toxicity. Overall, treatment was very well tolerated in
the four patients. No severe hematological toxicity or other
organ toxicity was observed after p.o. topotecan administration
at these doses. The third patient experienced fatigue (grade 2 on
a 4-point scale, National Cancer Institute Common Toxicity
Criteria), whereas the fourth patient had mild nausea and
vomiting.
DISCUSSION
This study was performed to explore the influence of
pleural and ascitic fluid on the pharmacokinetic behavior of
topotecan in cancer patients. Although the topotecan adminis-
tration was preceded by cisplatin infusion in this study in all
patients, important pharmacokinetic interactions that may have
influenced the generated data are not very likely: (a) comparison
of the kinetics of topotecan in clinical combination therapy
regimens with cisplatin with the kinetics of single-agent therapy
did not reveal an apparent interaction (12); and (b) using a
randomized cross-over design for the administration order, no
statistically significant differences in clinical pharmacokinetics
were observed between sequences of p.o. topotecan and i.v.
cisplatin (9).
Topotecan concentrations in pleural fluid and ascites were















1 Pleural 1 12.9 136 2.06 1.83 44.7
None 2 14.7, 18.3 119, 95.5 3.33, 6.50 2.17, 1.77 44.8, 43.5
2 Pleural 1 23.3 64.3 2.71 4.53 36.3
None 2 18.7, 17.0 80.0, 88.1 2.04, 2.30 4.43, 5.90 34.6, 35.8
3 Ascites 3 22.1 6 1.92 68.2 6 5.82 2.43 6 0.32 4.38 6 0.36 40.3 6 2.42
4 Ascites 3 5.80 6 1.82 155 6 61.2 1.51 6 0.65 3.00 6 0.58 39.2 6 5.3
None 3 6.28 6 1.42 148 6 12.1 1.16 6 0.15 3.40 6 0.66 40.5 6 8.4
a Data were obtained in both the presence and absence of third space fluids in each individual patient treated with topotecan doses, and the
treatment schedules were as given in Table 1. The AUC values were calculated by compartmental analysis, and data of patients 3 and 4 represent mean
values 6 SD.
b AUCL, area under the topotecan lactone plasma concentration-time curve; Cmax, peak plasma concentration of topotecan lactone; T1/2, apparent
terminal disposition half-life.
Fig. 1 Concentration versus
time plots of topotecan ex-
pressed as total drug (lactone
plus carboxylate) in plasma (E)
and ascites (patients 1 and 2) or
pleural fluid (patient 4; F) and
corresponding topotecan third-
space fluid:plasma concentra-
tion ratios (l) in patients 1 (A
and D), 2 (B and E), and 4 (C
and F).
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initially less than those in plasma, and several hours were
required for equilibrium to be attained between these fluids and
plasma. The limited surface area for topotecan diffusion relative
to the volumes of fluid and the fact that pleural fluid and ascites
are not well stirred, in addition to the hydrophilic nature of the
drug, likely contributed to the slow equilibrium kinetics. Over-
all, both pleural fluid and ascites represented only a small
additional compartment for topotecan distribution, particularly
in view of the already large topotecan steady-state volume of
distribution of 73-133 liters (13). Nevertheless, concentrations
equivalent to that in plasma were achieved after 8 h, and
topotecan appeared to be more slowly eliminated from the
pleural and peritoneal cavity than from plasma. This is in
keeping with earlier findings indicating slow peritoneal clear-
ance of topotecan and high peritoneal:plasma concentration
ratios of .10 after i.p. drug administration (14, 15).
Topotecan has been detected previously in ascites of two
patients treated with a combination of i.v. topotecan and p.o.
etoposide (16). However, the reported ascitic fluid:plasma con-
centration ratios were established by single-point measurements
at different times after administration. Because these concentra-
tion ratios were shown in our patients to be by no means
constant parameters during the dosing interval (Fig. 1, D–F),
single-point data are clearly inappropriate to directly compare
the extent of penetration by topotecan. Hence, the approach of
using paired AUC values in third space fluids and plasma, as
performed in the present study, should be considered the gold
standard to report these ratios. Although the described data on
topotecan accumulation are limited to only four patients, our
results suggest that oral administration of topotecan can produce
adequate drug distribution in pleural fluid and ascites at con-
centrations associated with significant antitumor activity in ex-
perimental models (17, 18). In this context, it is of particular
interest that topoisomerase I inhibitors were previously shown
to be highly S-phase specific and that cytotoxicity is a function
of the time to drug exposure above a certain threshold concen-
tration (19). The topotecan penetration and subsequent accumu-
lation in the third spaces thus might offer a potential therapeutic
advantage in that tumor cells in the thoracic and peritoneal
cavity are exposed to high local drug levels for prolonged time
periods. This concept has also been described recently for sys-
temic therapy with the structurally related camptothecin deriv-
ative irinotecan, although in contrast to topotecan, concentra-
tions appeared to decline in parallel with those in plasma (20).
The reason for this discrepant behavior is unknown, but it is
likely to reflect intrinsic differences in physicochemical and/or
pharmacokinetic properties of both compounds, including dif-
ferential binding to (plasma) proteins.
The plasma pharmacokinetics of topotecan revealed a sub-
stantial degree of interindividual variability, in line with previ-
ous observations (9).3 By comparing topotecan plasma levels in
the same patient before and after drainage of pleural or ascitic
fluid, no differences in rate of absorption and elimination be-
came apparent. The lack of increased systemic exposure to
topotecan in patients with massive third space volumes was
further substantiated by the lack of excess toxicity. Hence, in
contrast to clinical information on irinotecan treatment that
suggested an increased risk of severe toxicity in patients with
large pleural effusions or ascites (20), there was no evidence that
the severity of toxicity differed between study courses with and
without third space volumes in our patients treated with topo-
tecan.
In conclusion, we have shown that: (a) topotecan plasma
pharmacokinetics are unaltered in patients with third space
volumes; (b) topotecan can be safely administered to patients
with large pleural effusions or massive ascites; and (c) there
appears to be a substantial penetration of topotecan into these
third spaces, which may prove beneficial for local antitumor
effects.
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